Elezanumab (ABT-555)

Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries and multiple sclerosis.

Type of Molecule

Biologic

Target

RGMa

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Multiple Sclerosis (MS) n/a
Phase 1
Spinal Cord Injury n/a
Phase 1